Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on January 7, 2011. The report addresses corporate governance changes effective as of that date, specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
- Director Departure: William M. Daley resigned from the Board of Directors effective January 7, 2011, to accept the position of Chief of Staff to President Obama.
- Bylaw Amendment: The Board amended Article III, Section 2 of the By-laws to reduce the number of directors from fourteen to thirteen persons.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document serves solely to disclose the departure of a director and the corresponding amendment to the company's by-laws.
Investor Verification Checklist
- Confirm the effective date of William M. Daley's resignation (January 7, 2011).
- Verify the new authorized size of the Board of Directors (thirteen persons).
- Review the attached Exhibit 3.1 for the full text of the amended By-Laws.